218 related articles for article (PubMed ID: 34762643)
1. DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma.
Barenboim M; Kovac M; Ameline B; Jones DTW; Witt O; Bielack S; Burdach S; Baumhoer D; Nathrath M
PLoS Comput Biol; 2021 Nov; 17(11):e1009562. PubMed ID: 34762643
[TBL] [Abstract][Full Text] [Related]
2. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
Engert F; Kovac M; Baumhoer D; Nathrath M; Fulda S
Oncotarget; 2017 Jul; 8(30):48794-48806. PubMed ID: 27447864
[TBL] [Abstract][Full Text] [Related]
3. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
[No Abstract] [Full Text] [Related]
4. Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
Aref-Eshghi E; McGee JD; Pedro VP; Kerkhof J; Stuart A; Ainsworth PJ; Lin H; Volodarsky M; McLachlin CM; Sadikovic B
J Hum Genet; 2020 Oct; 65(10):865-873. PubMed ID: 32483276
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
Holme H; Gulati A; Brough R; Fleuren EDG; Bajrami I; Campbell J; Chong IY; Costa-Cabral S; Elliott R; Fenton T; Frankum J; Jones SE; Menon M; Miller R; Pemberton HN; Postel-Vinay S; Rafiq R; Selfe JL; von Kriegsheim A; Munoz AG; Rodriguez J; Shipley J; van der Graaf WTA; Williamson CT; Ryan CJ; Pettitt S; Ashworth A; Strauss SJ; Lord CJ
Sci Rep; 2018 Jul; 8(1):10614. PubMed ID: 30006631
[TBL] [Abstract][Full Text] [Related]
6. An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets.
Hill KE; Kelly AD; Kuijjer ML; Barry W; Rattani A; Garbutt CC; Kissick H; Janeway K; Perez-Atayde A; Goldsmith J; Gebhardt MC; Arredouani MS; Cote G; Hornicek F; Choy E; Duan Z; Quackenbush J; Haibe-Kains B; Spentzos D
J Hematol Oncol; 2017 May; 10(1):107. PubMed ID: 28506242
[TBL] [Abstract][Full Text] [Related]
7. [The clonal evolution of osteosarcomas].
Baumhoer D
Pathologe; 2016 Nov; 37(Suppl 2):163-168. PubMed ID: 27651058
[TBL] [Abstract][Full Text] [Related]
8. Combined analysis of DNA methylation and gene expression profiles of osteosarcoma identified several prognosis signatures.
Tian W; Li Y; Zhang J; Li J; Gao J
Gene; 2018 Apr; 650():7-14. PubMed ID: 29407229
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
Tian T; Shan L; Yang W; Zhou X; Shui R
Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
[TBL] [Abstract][Full Text] [Related]
10. Defining and Modulating 'BRCAness'.
Byrum AK; Vindigni A; Mosammaparast N
Trends Cell Biol; 2019 Sep; 29(9):740-751. PubMed ID: 31362850
[TBL] [Abstract][Full Text] [Related]
11. The insertion and dysregulation of transposable elements in osteosarcoma and their association with patient event-free survival.
Wang C; Liang C
Sci Rep; 2022 Jan; 12(1):377. PubMed ID: 35013466
[TBL] [Abstract][Full Text] [Related]
12. A support vector machine classifier for the prediction of osteosarcoma metastasis with high accuracy.
He Y; Ma J; Ye X
Int J Mol Med; 2017 Nov; 40(5):1357-1364. PubMed ID: 28901446
[TBL] [Abstract][Full Text] [Related]
13. Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart.
Angstadt AY; Motsinger-Reif A; Thomas R; Kisseberth WC; Guillermo Couto C; Duval DL; Nielsen DM; Modiano JF; Breen M
Genes Chromosomes Cancer; 2011 Nov; 50(11):859-74. PubMed ID: 21837709
[TBL] [Abstract][Full Text] [Related]
14. Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH.
Selvarajah S; Yoshimoto M; Ludkovski O; Park PC; Bayani J; Thorner P; Maire G; Squire JA; Zielenska M
Cytogenet Genome Res; 2008; 122(1):5-15. PubMed ID: 18931480
[TBL] [Abstract][Full Text] [Related]
15. A novel interplay between HOTAIR and DNA methylation in osteosarcoma cells indicates a new therapeutic strategy.
Li X; Lu H; Fan G; He M; Sun Y; Xu K; Shi F
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2189-2200. PubMed ID: 28730284
[TBL] [Abstract][Full Text] [Related]
16. Transcriptome Analysis Identifies Novel Prognostic Genes in Osteosarcoma.
Chen J; Guo X; Zeng G; Liu J; Zhao B
Comput Math Methods Med; 2020; 2020():8081973. PubMed ID: 33082842
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.
Branham MT; Campoy E; Laurito S; Branham R; Urrutia G; Orozco J; Gago F; Urrutia R; Roqué M
Breast Cancer Res Treat; 2016 Jan; 155(1):13-23. PubMed ID: 26610810
[TBL] [Abstract][Full Text] [Related]
18. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.
Lips EH; Laddach N; Savola SP; Vollebergh MA; Oonk AM; Imholz AL; Wessels LF; Wesseling J; Nederlof PM; Rodenhuis S
Breast Cancer Res; 2011 Oct; 13(5):R107. PubMed ID: 22032731
[TBL] [Abstract][Full Text] [Related]
19. Abnormal DNA methylation may contribute to the progression of osteosarcoma.
Chen XG; Ma L; Xu JX
Mol Med Rep; 2018 Jan; 17(1):193-199. PubMed ID: 29115427
[TBL] [Abstract][Full Text] [Related]
20. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
